Core Viewpoint - The collaboration between Nocera and Zenas marks a significant milestone in the internationalization process of Nocera, accelerating the global development and commercialization of its products, including Obeticholic Acid [1] Group 1: Internationalization and Partnerships - The partnership with Zenas is highlighted as a crucial step in Nocera's international expansion efforts [1] - The collaboration is expected to expedite the development and commercialization of Obeticholic Acid and other pipeline products globally [1] Group 2: Product Development Timeline - Obeticholic Acid is set to initiate Phase III trials for Primary Progressive Multiple Sclerosis (PPMS) in Q3 2025 and for Secondary Progressive Multiple Sclerosis (SPMS) in Q1 2026 [1] - The Phase III registration clinical trial for Obeticholic Acid in Immune Thrombocytopenic Purpura (ITP) in China has completed patient enrollment, with a market application submission expected in the first half of 2026 [1] - Zenas's core pipeline product, Obexelimab, is anticipated to report 12-week primary endpoint data from its Phase II clinical trial in the RMS field in Q4 2025, with 24-week data expected in Q1 2026 [1] Group 3: Product Pipeline and Market Position - Nocera has a comprehensive pipeline in hematological malignancies, autoimmune diseases, and solid tumors, indicating a broad market presence [1] - The core products are expected to drive performance, with ongoing advancements in the hematological, autoimmune, and solid tumor pipelines [1] - The successful business development (BD) of products like Obeticholic Acid is seen as a continuous coverage strategy for the company [1]